

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
1	15/SC/0409	183061	OPHT 4170 (AMD)	Number Agreed	8	8	Date Agreed	01/06/2017	8	07/04/2017	8	Recruitment Finished
2	16/SC/0161	186322	GO29438 PhaseII?Study-Atezolizumab?with?chemotherapy?in?Stage?IV?Non-Squamous	Number Agreed	4	4	Date Agreed	31/07/2017	5	20/04/2017	5	Recruitment Finished
3	15/LO/1236	183416	A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis	Number Agreed	1	1	Date Agreed	31/05/2017	0	21/04/2017	0	Recruitment Finished
4	16/SC/0018	191267	Study of CTX 4430 in Cystic Fibrosis Patients	Number Agreed	2	2	Date Agreed	15/05/2017	3	16/05/2017	3	Recruitment Finished
5	16/ES/0001	193859	GAST 5634	Number Agreed	3	3	Date Agreed	31/08/2017	1	22/05/2017	1	Withdrawn By Host
6	16/LO/1612	201997	Follow-up Study for Patients who Completed Study ALX0681-C301	Number Agreed	1	1	Date Agreed	30/11/2017	1	08/06/2017	1	Recruitment Finished
7	15/EM/0437	184390	COLUMBUS-AMD	Number Agreed	3	3	Date Agreed	30/06/2017	3	09/06/2017	3	Recruitment Finished
8	14/YH/1263	162807	CRIT 3719 (Intravascular glucose monitoring system)	Number Agreed	5	5	Date Agreed	30/06/2016	3	05/04/2017	3	Withdrawn By Sponsor
9	15/LO/1441	186018	HAEM 4790 (ALX0681-C301)	Number Agreed	3	3	Date Agreed	30/11/2017	1	08/06/2017	1	Recruitment Finished
10	16/EE/0011	194393	Phase III Otonomy Study 104-201508	Number Agreed	1	1	Date Agreed	30/06/2017	2	21/07/2017	2	Recruitment Finished
11	14/EM/0130	149751	NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy	Number Agreed	3	3	Date Agreed	31/08/2017	6	04/09/2017	6	Recruitment Finished
12	16/EE/0243	207331	A 6 Month Multicentre Phase 3, Open-Label extension Safety Study of OTO-104	Number Agreed	1	1	Date Agreed	30/11/2017	5	06/09/2017	5	Recruitment Finished
13	15/SC/0456	174561	CANC - 4254 - Anti-Pd-L1 Antibody (MPDL3280A) in Pediatric and Young Adult	Number Agreed	2	2	Date Agreed	30/09/2017	1	29/09/2017	1	Recruitment Finished
14	15/LO/2098	182147	CRIT 3822	Number Agreed	6	6	Date Agreed	31/12/2017	9	11/12/2017	9	Recruitment Finished
15	17/NW/0223	219119	Evaluation of PKU explore	Number Agreed	1	1	Date Agreed	31/12/2017	3	27/11/2017	3	Recruitment Finished
16	15/LO/0743	179335	HEPA 4444 (Hep B)	Number Agreed	4	4	Date Agreed	28/08/2018	3	18/09/2017	3	Withdrawn By Sponsor
17	14/EM/0215	152549	NCRN - 3109 Veliparib (ABT-888) in Unresectable BRCA-Associated Breas	Number Agreed	1	1	Date Agreed	30/11/2017	1	30/11/2017	1	Recruitment Finished
18	13/SC/0173	108971	VIABLE	Number Agreed	6	6	Date Agreed	01/06/2017	15	07/10/2017	15	Recruitment Finished

Performance Against Delivery Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure
19	16/EM/0408	211983	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	Number Agreed	3	3	Date Agreed	31/12/2017	5	10/04/2017	5	Recruitment Finished
20	16/EE/0325	204922	Venetoclax (ABT-199) in relapsed/refractory CLL (M15-550)	Number Agreed	4	4	Date Agreed	01/07/2018	0	20/12/2017	0	Recruitment Finished
21	15/LO/0141	169126	OPHT 3845	Number Agreed	4	4	Date Agreed	31/12/2018	0	18/10/2017	0	Withdrawn By Host
22	16/SC/0542	208245	OMASPECT	Number Agreed	1	1	Date Agreed	31/01/2018	2	20/11/2017	2	Withdrawn By Host
23	17/LO/0017	213632	Open-label Extension Study for Participants with Prostate Cancer	Number Agreed	2	2	Date Agreed	31/10/2017	2	01/10/2017	2	Recruitment Finished
24	14/WM/0013	143136	MCRN2947 (ALS-8176-503) Developing a new drug to treat infants hospitalised with RSV infection	Number Agreed	8	8	Date Agreed	31/03/2018	11	31/01/2018	11	Recruitment Finished
25	16/SW/0201	205118	OPHT 5713	Number Agreed	4	4	Date Agreed	31/01/2018	5	07/02/2018	5	Recruitment Finished
26	16/EM/0512	215840	TRILOGY	Number Agreed	4	4	Date Agreed	31/08/2018	4	31/03/2018	4	Recruitment Finished
27	16/NE/0142	202233	CANC 5578 (B9991010)	Number Agreed	5	5	Date Agreed	30/06/2018	2	19/01/2018	2	Recruitment Finished